Investors came into this Prenetics Global earnings print betting on a high growth healthcare stock that screens as deeply undervalued on some fair value models. The immediate verdict in the market told a cooler story. The stock slipped about 3.3% to US$18.76, even as the quarter showed sharply narrower losses and a much higher revenue base than earlier periods.

The headline is simple. Prenetics Global is still loss making, with basic earnings per share of roughly US$0.53 in the red for Q2, yet the earnings trend looks less punishing than recent quarters. That gap between a value heavy long term thesis and a cautious one day price reaction is what matters for you now.

Love the improving revenue base at Prenetics Global but concerned about the ongoing losses and valuation gap? You may also want to review our hand picked 20 high quality undiscovered gems for stocks that combine stronger fundamentals with potential upside.

Q2 2026 Earnings Summary

• Revenue, Q2 2026 vs. Q2 2025: US$46.488 million vs. US$14.964 million (very large year on year increase)
• Net Loss, Q2 2026 vs. Q2 2025: US$9.091 million loss vs. US$8.438 million loss (loss widened)
• Basic EPS, Q2 2026 vs. Q2 2025: US$0.53 loss per share vs. US$0.64 loss per share (loss per share narrowed)
• Trailing 12 Month Revenue, Q2 2026 vs. Q2 2025: US$154.593 million vs. US$57.051 million (very large increase over the year)

Prefer clean charts instead of another dense block of earnings figures? See Prenetics Global's full financial picture, including a clear view of its recent losses and revenue base, in the interactive company report for Prenetics Global.

Prenetics Global bull case faces a mixed stress test

Bulls argue that Prenetics Global is turning IM8’s early traction into a scalable, subscription heavy health and longevity platform with growing operating leverage. The latest quarter gives partial support to that story. Revenue of US$46.488 million and trailing 12 month revenue of US$154.593 million show that the brand is reaching a larger customer base and that IM8 is more than a niche launch. The loss per share narrowed to US$0.53 even though the net loss in dollars slightly widened to US$9.091 million. That suggests some early efficiency on a per share basis, which is consistent with claims of solid unit economics and repeat behavior. However, the business is still loss making and there is no clear sign yet in these numbers that operating leverage is flowing through strongly enough to confirm a near term path to profitability.

Bear case on losses and risk still has traction

Bears worry that IM8 is a concentrated, marketing heavy wellness business where customer acquisition costs and international expansion could keep Prenetics Global in the red and make the stock volatile. The Q2 figures do not remove that concern. Net loss increased to US$9.091 million even on a much larger revenue base, which hints that higher scale has not yet translated into lower absolute losses. The stock fell 3.3% on the earnings reaction and is down about 10% over 30 days, which shows investors are still cautious on execution and risk, including exposure to non core areas such as crypto. Revenue growth and a narrower per share loss are helpful, but they do not yet disprove worries about delayed profitability and sensitivity to marketing and international spend.

After a quarter where revenue scaled but absolute losses and recent share price declines still weigh on sentiment, it is fair to ask whether execution and dilution risks are just the surface. Review our independent risk analysis for Prenetics Global which shows 2 important warning signs

Stay Ahead With Simply Wall St

If Prenetics Global's fast growing revenue base and ongoing losses have your attention, register for free with Simply Wall St and add it to a Watchlist so you can track the share price against fair value models and watch for an entry point that fits your plan. Once you own the stock, use the Portfolio Command Center to cut through market noise and focus on key updates that matter for your holdings. For a longer term view, join the Community to see how other investors are thinking about risks, execution and valuation. This way you can review potential catalysts, identify red flags early and maintain an informed perspective on the market.

Seeking Alternatives Beyond Prenetics Global

Fresh ideas can move fast. Some stocks build quiet momentum, others drop out of favor before the crowd notices. Scan these curated shortlists while it matters and get in early.

• Spot potential breakout compounders before they hit every headline by checking a curated set of resilient companies in the 78 resilient stocks with low risk scores.
• Track where AI momentum could be flying next by reviewing a hand picked group of profitable businesses inside the 75 profitable AI stocks that aren't just burning cash.
• Catch income opportunities that others may overlook by scanning a focused shortlist of high yield payers through the 12 dividend fortresses.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.